Navigation Links
Next steps for Tenofovir gel: CONRAD and TIA sign license agreement
Date:6/14/2011

Arlington, VA, USA and Pretoria, South Africa -- CONRAD and the South African Government's Technology Innovation Agency (TIA) today announced a license agreement that grants TIA the rights to manufacture and distribute Tenofovir1% gel in Africa. TIA will in turn set up a joint venture for the manufacturing and distribution of the gel in South Africa and other licensed territory, which includes the African continent. The gel will be registered, manufactured and distributed by ProPreven, a joint venture involving TIA, Cipla Medpro and iThemba Pharmaceuticals.

Dr. Henry Gabelnick, Executive Director of CONRAD stated, "Although confirmatory results are necessary to secure regulatory approval, this license agreement creates a process to move approval and access forward. It's important to prepare for success in order to get this prevention tool to women who need it the most, as soon as possible."

Women who used Tenofovir 1% gel in a South African study called CAPRISA 004 had 39% fewer HIV infections and 51% fewer genital herpes infections compared to women who used a placebo gel. These results provided the first evidence that an antiretroviral drug delivered in a gel form can reduce sexually transmitted infections of HIV and herpes in women. Gilead Sciences licensed the drug royalty-free to CONRAD, who manufactured and supplied the gel for the trial.

"TIA has agreed to help facilitate the manufacture of this product so that it will be affordable and accessible to women, not only in South Africa, but the entire continent of Africa. While we have an enormous amount of work to accomplish before the product is available, we are creating a

mechanism to expedite the process to the market," said Pontsho Maruping, Group Executive: Sectors at TIA. "We hope this can be accomplished in the next three years," Ms. Maruping added.

CONRAD is spearheading regulatory work toward registration in the U.S., South Africa and Europe.
'/>"/>

Contact: Annette Larkin
alarkin@conrad.org
703-772-6427
CONRAD
Source:Eurekalert

Page: 1 2

Related medicine news :

1. New Lumension Webcast Highlights Key Steps to Prepare Healthcare Firms and Business Associates to Comply with New HITECH Act
2. UAB-led study shows simple steps could reduce stillbirths by up to 1 million
3. KID HEALTHY-Steps to Healthy Living Kicks Off 2010 Campaign to Make Southern California Kids and Families Healthier
4. New York Medical Malpractice Attorney Recommends Cancer Patients Take Precautionary Steps Before Undergoing Radiation Therapy
5. Consumers over age 50 should consider steps to cut copper and iron intake
6. B. Eliot Cole, MD, Steps Down as Executive VP at Aventine Healthsciences and Executive Director of American Society of Pain Educators
7. Strep steps up in urinary tract infections
8. Attain Fertility Offers 3 Steps to Protect Emotional Well-being While Trying to Get Pregnant
9. More Steps a Day Lead to Better Health
10. Khannna Institute to offer Crystalens in Quarter Diopter Steps
11. Five Essential Steps to Choosing Toning Footwear
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... The federal litigation established for Lipitor ... caused patients to develop Type 2 diabetes continues to ... South Carolina. According to court documents, the proceeding’s next ... at 10:00 a.m. In advance of the Conference, the ... report to the Court by March 19, 2015. (In ...
(Date:3/4/2015)... VIENNA, Austria (PRWEB) March 04, 2015 ... to reduce subjectivity in density assessment and help ... focus of numerous abstracts accepted for presentation at ... 3-8, 2015. Ten abstracts - eight posters ... of Volpara Solutions’ automated breast density and quantitative ...
(Date:3/4/2015)... More than a year after announcing ... with low testosterone treatments ( http://www.testosteronelawsuithub.com/ ), the U.S. ... now require manufacturers to warn patients that this class ... and strokes. In a Drug Safety Communication ... it was requiring testosterone manufacturers to update the drugs’ ...
(Date:3/4/2015)... The print component of “Organic Living” ... Chronicle with a circulation of approximately 173,000 copies and ... is distributed nationally through a vast social media strategy ... partner outlets. To explore the digital version of the ... composed of heat-dried microbes that have digested the organic ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 The ... $236.8 billion in 2014 and is estimated to ... CAGR of 4.0% from 2014 to 2019. , ... Gas Market for an analysis of industry trends, ... The global liquefied petroleum gas market is classified ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 2Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 5Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 4Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 2Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 3
... Specialized one- and two-year Indiana University graduate ... number of health information technology specialists in Indiana ... thanks in part to Recovery Act funding. Two ... learning opportunities. In collaboration with the Regenstrief ...
... HIV could help to develop a vaccine to build antibodies, ... has found. By investigating the action of the human ... to identify that the virus evolves to evade or ,escape, ... Melbourne and one of the senior authors on the paper ...
... pylori , a common stomach bacteria, minimizes the effects of ... of Michigan Medical School scientists. The study published in ... of investigators assembled by senior author John Y. Kao, M.D. ... professor in U-M,s Department of Internal Medicine. The findings indicate ...
... 4, 2011) Autism Speaks, the world,s largest autism ... announced the top awards for "Autism Connects", the international ... by student competitors selected by a juried panel demonstrate ... (ASD) to better connect with the world around them, ...
... 5 (HealthDay News) -- In people with advanced kidney cancer, ... is working, with high blood pressure linked to longer survival, ... of 544 people being treated with the drug sunitinib (Sutent) ... maximum systolic blood pressure reached 140 mmHg or higher survived ...
... New Rochelle, NY, May 5, 2011When children or adolescents ... the disorder, it may impair their ability to manage ... asthma-related anxiety is described in an article in ... published by Mary Ann Liebert, Inc. The article is ...
Cached Medicine News:Health News:IU-Regenstrief programs targeted to alleviate shortage of health IT workforce 2Health News:DNA from common stomach bacteria minimizes effects of colitis, U-M study says 2Health News:Autism Speaks and Core77 Magazine name winners of 'Autism Connects' design challenge 2Health News:Autism Speaks and Core77 Magazine name winners of 'Autism Connects' design challenge 3Health News:Autism Speaks and Core77 Magazine name winners of 'Autism Connects' design challenge 4Health News:Blood Pressure May Hint at Kidney Cancer Outcome 2
(Date:3/4/2015)... 2015 UPM Pharmaceuticals, a division of Gregory ... Pharmaceuticals to manufacture Flibanserin 100 mg tablets. Sprout has ... first drug approved to treat hypoactive sexual desire disorder ... The tablets will be manufactured at UPM,s ... . Dr. John M. Gregory ...
(Date:3/4/2015)... March 4, 2015 From March 8-11, ... 2015 Distribution Management Conference and Expo in ... HDMA,s largest supply chain education event, attended by ... who keep the pharmaceutical distribution industry moving. Attracting ... and legislative issues important to healthcare distribution and ...
(Date:3/4/2015)... 4, 2015 Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer ... and cancer, today announced that James A. Joyce ... corporate overview at the 27th Annual ROTH Conference on ... Laguna Niguel, California . To learn more ... A live webcast of the presentation will ...
Breaking Medicine Technology:UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets 2UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets 3Aethlon Medical to Present at the 27th Annual ROTH Conference 2
... Biosciences, Inc., a privately held company leading the ... announces one poster presentation and two oral presentations ... meeting on November 14, 2011 during the 9:00 ... presentations highlight results from Regado,s pipeline of antithrombotic ...
... GenturaDx today announced that it will present data from alpha ... Pathology 2011 Annual Meeting on Friday, November 18 from 2:15 ... Of Assay Performance Between Cell Culture And A Rapid Automated ... will address the capability of the GenturaDx IDbox™ System to ...
Cached Medicine Technology:Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH 2Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH 3Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH 4GenturaDx to Host Poster Presentation at Association for Molecular Pathology 2011 Annual Meeting 2
... CHF test device utilizes ... solid-phase chromatographic immunoassay technology. ... has been dispensed into ... StatusFirst CHF test device ...
... The Vision5L ... high-quality 5- or ... with a signal ... transfer using a ...
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
... test face is used to evaluate both low ... (high, 25% and 12.5%) of LogMAR acuity (20/16 ... as well as the two spatial frequencies of ... widely used for cataract documentation because eye doctors ...
Medicine Products: